Trial of vaccine for brain cancer misses primary endpoint
A randomized phase 2B trial of a novel peptide-based vaccine missed its primary endpoint, as the immunotherapy failed to significantly extend survival compared with placebo in newly diagnosed glioblastoma, according to a press release. However, topline data showed SurVaxM (MimiVax Inc.) may have the potential to delay…